Virus News and Research

Latest Virus News and Research

Atlantic examines flu vaccine, antiviral skepticism

As countries around the world roll out H1N1 (swine flu) virus vaccine campaigns, the Atlantic examines, "[W]hat if everything we think we know about fighting influenza is wrong?"

15 Oct 2009

Richmont Sciences to market PURE’s antimicrobial SDC disinfectants

PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE’s revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

Patients who are severely ill with H1N1 are at risk for developing PE, says study

Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.

14 Oct 2009

DIATHERIX Laboratories granted EUA for H1N1-09 Influenza Test

DIATHERIX Laboratories, Inc. is pleased to announce it has been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its DIATHERIX H1N1-09 Influenza Test.

14 Oct 2009

BioMedReports electronic newsletter releases an article about Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV, and hepatitis testing, today announced the Company is the subject of a cover page story in the prestigious BioMedReports electronic newsletter and portal.

14 Oct 2009

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

14 Oct 2009

Researchers discover compounds that show promise as novel treatments for AIDS

While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

Imaging as a tool to identify severe cases of H1N1

Researchers at the National Institutes of Health (NIH) have found that imaging can now be used as a tool for identifying severe cases of H1N1 and may play a key role in understanding the pathogenesis of the virus, possibly leading to earlier diagnoses of severe cases in the future, according to a study published online today in the American Journal of Roentgenology. The study will be published in the December issue of AJR.

14 Oct 2009

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

14 Oct 2009

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.

14 Oct 2009

Do not underestimate the serious impact of the H1N1 virus, say researchers

A research team has warned medical experts in the Northern Hemisphere not to underestimate the serious impact of the H1N1 (Swine flu) virus with a new report showing that many patients who were critically ill with the virus required prolonged life support treatment with heart-lung machines.

14 Oct 2009

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Early action, especially rapid rollout of vaccines, is extremely effective in reducing the attack rate of the H1N1 influenza virus, according to a simulation model of a pandemic outbreak reported in a new study in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

14 Oct 2009

American Lung Association to raise awareness about the seriousness of seasonal influenza

In the spirit of "healthy competition," the American Lung Association in Minnesota is teaming up with the Minneapolis and St. Paul Fire Departments to raise awareness about the seriousness of seasonal influenza and the importance of vaccination this year.

14 Oct 2009

New Ultra Sensitive facemasks to protect against seasonal and swine flu

BIOSAFE, Inc., a company that manufactures and sells a novel antimicrobial polymer, has announced that they are launching in specific markets outside the United States through a unique facemask treated with BIOSAFE(®). Crosstex' new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms such as MRSA, VRE, and Staph immediately upon contact, and have further proven to be effective against Influenza A strains such as seasonal flu and the novel H1N1 virus.

14 Oct 2009

Study says critical illness among Canadian patients with H1N1 occurred rapidly after hospital admission

Critical illness among Canadian patients with 2009 influenza A(H1N1) occurred rapidly after hospital admission, often in young adults, and was associated with severely low levels of oxygen in the blood, multi-system organ failure, a need for prolonged mechanical ventilation, and frequent use of rescue therapies, according to a study to appear in the November 4 issue of JAMA.

13 Oct 2009

New RNA repair and modification system in bacteria discovered

In new papers appearing this month in Science and the Proceedings of the National Academy of Sciences, University of Illinois biochemistry professor Raven H. Huang and his colleagues describe the first RNA repair system to be discovered in bacteria.

13 Oct 2009

Users can share interactive information on Humanpapilloma Virus anonymously

A new Facebook application has been launched to help educate, motivate and mobilize people to prevent the spread of Humanpapilloma Virus (HPV). "Fact Check: HPV" (www.hpvfactcheck.org) allows users to take an interactive, educational quiz about HPV, find additional resources, and commit to take action, while even allowing concerned friends to anonymously share the application with peers.

13 Oct 2009

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that it will cover 100% of the cost associated with the administration of the H1N1 vaccine for employees and their eligible dependents enrolled in a fully-insured Guardian medical plan.

13 Oct 2009